Phase II study of alemtuzumab (CAMPATH-1®) in patients with HTLV-1-associated adult T-cell leukemia/lymphoma

PURPOSE: Therapeutic regimens for ATL are limited with unsatisfactory results, thereby warranting development of novel therapies. This study investigated antitumor activity and toxicity of alemtuzumab with regard to response, duration of response, progression free survival, and overall survival in p...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Sharma, Kamal, Janik, John E., O’Mahony, Deirdre, Stewart, Donn, Pittaluga, Stefania, Stetler-Stevenson, Maryalice, Jaffe, Elaine S., Raffeld, Mark, Fleisher, Thomas A., Lee, Cathryn C., Steinberg, Seth M., Waldmann, Thomas A., Morris, John C.
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5215752/
https://ncbi.nlm.nih.gov/pubmed/27486175
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-16-1022
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados